Eagle Pharmaceuticals chief scientific officer to step down | S&P Global Market Intelligence

WORKFLOW SOLUTIONS
PRODUCTS
See More S&P Global Solutions
CONTENT
SECTOR-SPECIFIC INSIGHTS
More ways we can help
NEWS & RESEARCH TOPICS
See More
Featured Events
Hosted EventsThe Future of Credit and Risk Management: Trends, Challenges, and Opportunities in Europe
- 03/28/2023
- CIRCL, Amsterdam
- 08:30 - 13:00 Central European Time
WebinarPractical steps to achieve net-zero underwriting – Set a baseline, define targets and take action
- 03/30/2023
- Live, Online
- 10:00 am - 11:00 am GMT
WebinarPolitics & Policy: Sustainability Measures and Physical Risks
- 03/30/2023
- Live, Online
- 10:00 am - 11:00 am EDT
PLATFORMS
OTHER PRODUCTS
- Research Online
- 451 Research
See All Product Logins

Eagle Pharmaceuticals chief scientific officer to step down

Insight Weekly: SVB fallout limited; US rents up; renewable natural gas investments flow in

A Cloud Migration Plan for Corporations featuring Snowflake®

Investor Activism Campaigns Hit Record High in 2022

Essential IR Insights Newsletter - February 2023

23 Feb, 2018 | 00:13

Eagle Pharmaceuticals chief scientific officer to step down

Author Mirza Salam Ahmed
Theme Healthcare & Pharmaceuticals

Eagle Pharmaceuticals Inc. said Steven Krill, executive vice president and chief scientific officer, will leave the company Feb. 26.

Krill has been chief scientific officer since February 2013.

Woodcliff Lake, N.J.-based Eagle Pharmaceuticals develops injectable products primarily in the critical care and oncology areas.